Nintedanib Alternatives Compared
| Nintedanib | Ofev (nintedanib) | Esbriet (pirfenidone) |
|
|---|
| Nintedanib | Ofev (nintedanib) | Esbriet (pirfenidone) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Idiopathic Pulmonary Fibrosis, Chronic Fibrosing Interstitial Lung Disease With A Progressive Phenotype, Systemic Sclerosis-Associated Interstitial Lung Disease. Nintedanib may also be... View more |
Prescription only
Prescribed for Idiopathic Pulmonary Fibrosis, Chronic Fibrosing Interstitial Lung Disease With A Progressive Phenotype, Systemic Sclerosis-Associated Interstitial Lung Disease. Ofev may also be used... View more |
Prescription only
Prescribed for Idiopathic Pulmonary Fibrosis. Esbriet may also be used for purposes not listed in this medication guide. |
Related suggestions Idiopathic Pulmonary Fibrosis
|
|||||||||||||||
| More about Nintedanib | More about Ofev (nintedanib) | More about Esbriet (pirfenidone) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Nintedanib has an average rating of 7.7 out of 10 from a total of 36 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 6% reported a negative effect. |
Ofev has an average rating of 7.6 out of 10 from a total of 27 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 7% reported a negative effect. |
Esbriet has an average rating of 7.5 out of 10 from a total of 11 ratings on Drugs.com. 64% of reviewers reported a positive effect, while 9% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all Nintedanib side effects |
View all Ofev side effects |
View all Esbriet side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Ofev prices |
View all Esbriet prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Ofev |
N/A |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
9.5 hours |
9.5 hours |
3 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 252 drugs are known to interact with Nintedanib:
|
A total of 252 drugs are known to interact with Ofev:
|
A total of 162 drugs are known to interact with Esbriet:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
|
|
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
N/A |
October 15, 2014 |
October 15, 2014 |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.